L3.E2

Autacoids and Histamine Overview

• Definition of Autacoids:

  • Derived from the Greek words autos (meaning self) and akos (meaning remedy or healing).

  • Autacoids are endogenous biological substances that are synthesized and released locally to exert local physiological or pathological actions on surrounding tissues or on the producing cell itself.

• Modes of Cellular Action:

  • Autocrine: The synthesized and secreted substance acts directly on the membrane receptors of the exact same cell that produced it.

  • Paracrine: The substance is synthesized and released by one local cell type and diffuses through interstitial fluid to act on neighboring, different cell types without entering the systemic bloodstream.

  • Endocrine: Distinct from autacoids; endocrine substances (hormones) are secreted into the vascular system and travel via blood circulation to distant organs to exert their effects.

Histamine Synthesis, Storage, and Release

• Biogenic Amine Structure and Synthesis:

  • Histamine is a biogenic amine produced from the amino acid histidine.

  • Synthesis is catalyzed by the enzyme histidine decarboxylase, which removes the carboxyl radical ($-\text{COOH}$) from histidine to form histamine.

• Primary Tissue Storage Sites:

  • Mast Cells and Basophils: Main cellular storage sites. Histamine is preformed and packaged into intracellular granules (appearing as dense black cytoplasmic granules under microscopic imaging).

  • Central Nervous System (CNS): Synthesized and stored within histaminergic neurons.

  • Gastrointestinal Tract: Synthesized and stored within enterochromaffin-like (ECL) cells located in the gastric mucosa.

• Two-Step Mast Cell Degranulation Mechanism:

  • Step 1: Sensitization (Initial Exposure):

    • An individual is exposed to a specific allergen for the first time.

    • The immune system responds by producing allergen-specific $IgE$ antibodies (and associated $IgG$ responses).

    • These antibodies bind anchored to high-affinity receptors expressed on the surface membrane of tissue mast cells and circulating basophils.

  • Step 2: Re-exposure and Degranulation:

    • Upon subsequent exposure to the same allergen, the allergen cross-links the membrane-bound antibodies on sensitized mast cells.

    • Cross-linking triggers immediate exocytosis (degranulation) of the intracellular granules, releasing massive quantities of histamine alongside other inflammatory mediators into the extracellular space.

    • Released histamine acts locally as a potent cytokine and inflammatory mediator.

Histamine Receptor Subtypes and Physiological Actions

• General Receptor Characteristics:

  • All four known histamine receptor subtypes ($H_1$, $H_2$, $H_3$, $H_4$) belong to the G-Protein Coupled Receptor (GPCR) superfamily.

  • Receptors are anchored in the cell membrane and trigger distinct intracellular signaling cascades depending on their coupled G-protein subtype ($G_q$, $G_s$, or $G_i$).

• $H_1$ Receptor (Stimulatory):

  • G-Protein Coupling: Coupled to $G_q$. Activation stimulates phospholipase C, increasing inositol trisphosphate ($IP_3$) and diacylglycerol (DAG), leading to elevated intracellular calcium ($[Ca^{2+}]_i$).

  • Anatomic Locations: Vascular endothelium, bronchial smooth muscle, skin, and central nervous system.

  • Physiological Effects:

    • Vascular Endothelium: Induces arterial vasodilation and increases vascular permeability, leading to fluid extravasation, tissue swelling, and edema.

    • Bronchial Smooth Muscle: Promotes bronchoconstriction, narrowing airways and increasing airway resistance.

    • Skin: Stimulates peripheral nerve endings, causing intense pruritus (itching).

    • CNS: Promotes arousal, excitement, and maintenance of wakefulness.

• $H_2$ Receptor (Stimulatory):

  • G-Protein Coupling: Coupled to $G_s$. Activation stimulates adenylyl cyclase, increasing intracellular cyclic adenosine monophosphate ($cAMP$). Modulates some immune cell activity.

  • Anatomic Locations: Gastric parietal cells, cardiac tissue, vascular smooth muscle, and certain immune cells.

  • Physiological Effects:

    • Gastric Parietal Cells: Directly stimulates gastric acid ($HCl$) secretion into the stomach lumen.

    • Cardiac Tissue: Increases heart rate (positive chronotropy) and myocardial contractility (positive inotropy).

    • Endocrine/Vascular: Can stimulate epinephrine/adrenaline release and modulate blood clot formation.

• $H_3$ Receptor (Inhibitory):

  • G-Protein Coupling: Coupled to $G_i$. Activation inhibits adenylyl cyclase, decreases $cAMP$, and reduces calcium influx, depressing cellular responses.

  • Anatomic Location: Primarily located presynaptically in the CNS (functions as an autoreceptor or heteroreceptor).

  • Physiological Effects:

    • Exerts negative feedback to inhibit the synthesis and presynaptic release of histamine and other neurotransmitters, including acetylcholine, norepinephrine, and serotonin ($5-HT$). Reduction in release of neurotransmitter secretion.

    • Regulates wakefulness, appetite, and sleep-wake cycles.

• $H_4$ Receptor (Inhibitory):

  • G-Protein Coupling: Coupled to $G_i$. Decreases $cAMP$ and intracellular calcium influx.

  • Anatomic Location: Bone marrow, eosinophils, neutrophils, T-cells, and other immunocompetent cells.

  • Physiological Effects: Regulates leukocyte chemotaxis, immune cell activation, visceral pain, and allergic tissue inflammation.

Anaphylaxis and Hypersensitivity Pathophysiology

• Anaphylactic Shock:

  • A sudden, massive, systemic release of histamine and co-mediators into circulation within minutes of exposure to an allergen.

  • Systemic $H_1$-mediated vasodilation reduces systemic vascular resistance to near zero, causing severe hypotension, vascular collapse, and shock.

  • Concurrent profound fluid extravasation causes generalized systemic edema, facial swelling, laryngeal edema, and severe airway compromise.

• Airway Reactivity:

  • $H_1$ activation drives airway smooth muscle contraction (bronchoconstriction), dramatically reducing peak expiratory flow. Asthmatic individuals exhibit heightened responsiveness.

• First-Line Emergency Intervention:

  • Epinephrine (Adrenaline) is the drug of choice for anaphylaxis.

  • Mechanism: Acts functional antagonist to histamine. Epinephrine stimulates $\beta_2$-adrenergic receptors to induce rapid bronchodilation and \text{\alpha}_1-adrenergic receptors to induce systemic vasoconstriction, reversing life-threatening hypotension and mucosal edema.

  • Limitation of Antihistamines: $H_1$ blockers only target histamine receptors and fail to reverse active bronchospasm or counteract other unblocked inflammatory mediators (such as leukotrienes and prostaglandins).

• Step-wise Escalation for Allergic Reactions:

  • Step 1: $H_1$ Receptor Antagonists (provides partial relief by blocking histamine actions).

  • Step 2: Systemic or Topical Corticosteroids (exert broad anti-inflammatory action by suppressing gene transcription of multiple cytokines, leukotrienes, and prostaglandins).

First-Generation $H_1$ Antihistamines

• Pharmacodynamic Mechanism:

  • Act as reversible, competitive inverse agonists at the $H_1$ receptor.

  • Shift the conformational equilibrium of the $H_1$ receptor toward the inactive state, maintaining inactivity even in the presence of basal receptor turnover.

• Physicochemical and Pharmacokinetic Properties:

  • Highly lipophilic (lipid-soluble) molecules with low molecular weight.

  • Readily cross the blood-brain barrier (BBB) into the CNS.

  • Rapidly absorbed following oral administration with peak effect occurring within 1 to 2 hours; duration of action is typically 4 to 6 hours.

  • Extensively metabolized by hepatic cytochrome P450 enzymes.

• Off-Target Binding and Adverse Effects:

  • CNS $H_1$ and $H_3$ Blockade: Causes marked central nervous system depression, leading to sedation, drowsiness, cognitive impairment, slowed reaction time, confusion, and delirium.

  • Central Muscarinic ($M$) Receptor Blockade: Produces classical anticholinergic side effects:

    • Urinary retention

    • Blurred vision (cycloplegia/mydriasis)

    • Dry mouth (xerostomia)

    • Constipation

  • \text{\alpha}_1-Adrenergic Receptor Blockade: Blocks vascular \text{\alpha}_1 receptors, causing orthostatic hypotension (sudden drop in blood pressure upon standing, causing lightheadedness or syncope).

  • Voltage-Gated Sodium Channel Blockade: Membrane-stabilizing action that produces local anesthetic effects.

• Specific First-Generation Agents:

  • Promethazine:

    • Extremely lipophilic with strong central sedating effects.

    • Prominently used in psychiatry as an adjunct to antipsychotic regimens to control acute agitation and enhance calming effects.

    • Used off-label/clinically to manage acute drug-induced extrapyramidal symptoms (EPS) caused by dopamine receptor antagonists.

    • Exerts marked \text{\alpha}_1-blockade leading to orthostatic hypotension.

  • Cyproheptadine:

    • Possesses unique antagonist properties at central serotonin ($5-HT$) receptors in addition to $H_1$ blockade.

    • Acts centrally to stimulate appetite; frequently formulated as a syrup to treat failure to thrive or poor appetite in pediatric patients.

  • Doxylamine:

    • Highly sedating agent incorporated into OTC nighttime combination cold/flu products (e.g., NyQuil) to promote sleep in symptomatic patients.

• Special Populations and Warnings:

  • Pediatrics:

    • High risk of accidental overdose and dosing errors with liquid formulations.

    • May induce paradoxical excitation (hyperactivity, restlessness, insomnia) instead of sedation.

  • Geriatrics (Beers Criteria Guidelines):

    • Potentially inappropriate medication for older adults due to high risk of confusion, delirium, cognitive decline, constipation, and urinary retention.

    • Significantly increases risk of instability, falls, and resulting femoral/hip fractures.

    • Strictly contraindicated/avoided in patients with benign prostatic hyperplasia (BPH) or urinary retention (worsens outflow obstruction) and narrow-angle glaucoma (increases intraocular pressure).

Second-Generation $H_1$ Antihistamines

• Physicochemical and Pharmacokinetic Differences:

  • Designed with lower lipophilicity and higher polarity/ionization at physiological pH.

  • Act as substrates for the P-glycoprotein (P-gp) efflux pump located at the blood-brain barrier, which actively pumps the drug out of the CNS.

  • Demonstrate minimal blood-brain barrier penetration, drastically reducing central sedation and cognitive impairment.

  • Extended duration of action (up to 24 hours), enabling once-daily dosing and improving patient compliance.

• Specific Second-Generation Agents:

  • Fexofenadine:

    • Non-sedating $H_1$ antagonist among the top 200 most prescribed medications.

    • Lacks central antiemetic and motion sickness properties due to lack of CNS penetration.

  • Cetirizine:

    • Top-prescribed $H_1$ antagonist.

    • In addition to competitive $H_1$ receptor blockade, it directly inhibits mast cell degranulation and limits the release of histamine and secondary inflammatory mediators.

  • Loratadine:

    • A prodrug requiring hepatic oxidative cleavage via cytochrome CYP3A4 to form its active metabolite (desloratadine).

• Cytochrome P450 Drug Interactions:

  • Many second-generation agents are extensively metabolized by CYP3A4.

  • Co-administration with potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin) increases the area under the concentration-time curve (AUC) of the antihistamine, elevating the risk of adverse events.

  • Certain historical agents were restricted or withdrawn by the FDA due to drug interaction-induced QT interval prolongation and torsades de pointes arrhythmias.

Clinical Applications and Patient Counseling for $H_1$ Antihistamines

• Indications:

  • Symptomatic relief of allergic rhinitis, urticaria, allergic conjunctivitis, pruritus, hives, sneezing, and localized edema.

  • Motion sickness prevention (first-generation agents only; block presynaptic histaminergic inputs from the vestibular nucleus to the emetic center).

• Motion Sickness Non-Pharmacological Secret:

  • Motion sickness stems from a sensory mismatch between visual inputs and vestibular spatial perception (e.g., sitting in the backseat of a moving car or inside an interior ship cabin).

  • Management: Move to the front seat or deck and stare continuously at the visual horizon to align visual cues with motion perception.

• Patient Counseling Points:

  • Advise second-generation non-sedating agents for daytime use, especially in ambulatory patients, drivers, or individuals operating machinery.

  • Warn patients regarding additive CNS depression when combining first-generation antihistamines with alcohol, sedatives, hypnotics, or opioids.

  • Audit over-the-counter (OTC) combination products (e.g., multi-symptom cold/flu formulations) to prevent duplicate therapy and inadvertent stacking of hidden first-generation antihistamines.

  • Counsel patients with hepatic impairment that dose reductions may be required to prevent drug accumulation and systemic toxicity.

Pathophysiology of Acid-Related Gastrointestinal Disorders

• Gastroesophageal Reflux Disease (GERD):

  • Inappropriate relaxation of the lower esophageal sphincter resulting in gastric acid and pepsin refluxing into the esophagus.

  • Chronic acid exposure injures the esophageal squamous epithelium, causing erosive esophagitis, strictures, Barrett's esophagus, and elevated risk of esophageal adenocarcinoma.

• Dyspepsia:

  • Symptomatic complex characterized by persistent or recurrent upper abdominal pain, fullness, or burning without demonstrable structural lesions on upper endoscopy.

• Peptic Ulcer Disease (PUD):

  • Focal, mucosal mucosal breaks penetrating through the muscularis mucosae in the stomach or duodenum.

  • Primary Etiologies: Helicobacter pylori bacterial infection and systemic mucosal barrier disruption from Non-Steroidal Anti-inflammatory Drugs (NSAIDs).

  • Complications: Major upper gastrointestinal bleeding, arterial hemorrhage, ulcer perforation, and peritonitis.

• Parietal Cell Acid Secretion Physiology:

  • The parietal cell secretes hydrochloric acid ($HCl$) into the gastric lumen via the apical membrane $H^+/K^+$ ATPase proton pump.

  • Three Primary Stimulatory Pathways:

    1. Acetylcholine (ACh): Neural pathway released from postganglionic vagal fibers; binds to $M_3$ muscarinic receptors ($G_q$-coupled pathway $\rightarrow$ elevated intracellular $Ca^{2+}$).

    2. Gastrin: Endocrine/paracrine hormone released by antral G cells into local circulation; binds to Cholecystokinin-2 ($CCK_2$ / G) receptors ($G_q$-coupled pathway $\rightarrow$ elevated intracellular $Ca^{2+}$).

    3. Histamine: Paracrine substance released locally by gastric enterochromaffin-like (ECL) cells; binds to parietal cell $H_2$ receptors ($G_s$-coupled pathway $\rightarrow$ elevated intracellular $cAMP$).

Antacids: Mechanisms, Formulations, and Clinical Properties

• General Mechanism of Action:

  • Weak basic inorganic salts that directly react chemically with gastric hydrochloric acid ($HCl$) in the stomach lumen.

  • Neutralize gastric acid to form a neutral salt and water, rapidly elevating gastric pH above 4.0 and reducing peptic activity.

  • Provide rapid, immediate symptom relief but possess a short duration of action dependent on gastric emptying rates.

  • Liquid suspension formulations demonstrate a faster onset of action than solid oral tablets.

• Specific Antacid Formulations:

  • Sodium Bicarbonate ($NaHCO_3$):

    • Chemical Reaction: $NaHCO_3 + HCl \rightarrow NaCl + H_2O + CO_2\uparrow$

    • Characteristics: Highly soluble, extremely rapid onset.

    • Drawbacks: Releases carbon dioxide ($CO_2$) gas causing belching, flatulence, and gastric distension. High systemic sodium absorption causes fluid retention, volume expansion, and elevation of blood pressure.

    • Contraindications/Cautions: Avoid in patients with heart failure, hypertension, cirrhosis, or severe renal insufficiency.

  • Calcium Carbonate ($CaCO_3$):

    • Chemical Reaction: $CaCO_3 + 2HCl \rightarrow CaCl_2 + H_2O + CO_2\uparrow$

    • Characteristics: Moderate onset, longer duration than sodium bicarbonate. Does not deliver a sodium load, making it safer for cardiac patients.

    • Drawbacks: Generates $CO_2$ gas. Chronic, heavy ingestion (especially when taken alongside rich dairy sources of calcium) causes Milk-Alkali Syndrome, characterized by hypercalcemia, renal impairment/calcification, and metabolic alkalosis.

  • Magnesium Hydroxide ($Mg(OH)_2$):

    • Chemical Reaction: $Mg(OH)_2 + 2HCl \rightarrow MgCl_2 + 2H_2O$

    • Characteristics: No gas generation or gastric distension.

    • Gastrointestinal Action: Poorly absorbed magnesium salts act osmotically in the intestinal lumen to draw in fluid, producing osmotic diarrhea. Ideal for patients presenting with concomitant constipation.

    • Toxicity: In patients with renal failure, unexcreted magnesium accumulates systemically, posing a high risk for hypermagnesemia and cardiac arrhythmias.

  • Aluminum Hydroxide ($Al(OH)_3$):

    • Chemical Reaction: $Al(OH)_3 + 3HCl \rightarrow AlCl_3 + 3H_2O$

    • Gastrointestinal Action: Aluminum ions relax intestinal smooth muscle and bind bile salts, leading to constipation and delayed gastric emptying.

    • Toxicity: Aluminum accumulates in severe renal failure, causing neurotoxicity, encephalopathy, and osteomalacia.

  • Magnesium Hydroxide + Aluminum Hydroxide Combination Formulations:

    • Formulated by pharmaceutical manufacturers to utilize the pro-diarrheal effect of magnesium to directly counteract the constipating effect of aluminum, maintaining neutral bowel motility without altering intestinal transit time.

• Drug Interactions via Chelation:

  • Polyvalent cations ($Mg^{2+}$, $Al^{3+}$, $Ca^{2+}$) present in antacids bind and form insoluble chemical complexes (chelation) with concomitant oral medications.

  • Significantly reduces the oral bioavailability of key drugs, notably fluoroquinolones (e.g., moxifloxacin, ciprofloxacin) and tetracyclines.

  • Management: Separate administration times by taking oral medications 2 hours before or 4 to 6 hours after antacid ingestion.

$H_2$ Receptor Antagonists ($H_2$RAs): Mechanisms and Pharmacokinetics

• Mechanism of Action:

  • Competitive, selective inhibitors of $H_2$ receptors located on the basolateral membrane of gastric parietal cells.

  • Block histamine-induced activation of adenylyl cyclase, reducing intracellular $cAMP$ levels and suppressing basal and stimulated gastric acid secretion.

• Diurnal Acid Suppression Profile:

  • Exert their most profound effect on nocturnal gastric acid secretion (basal night-time secretion is driven predominantly by histaminergic tone).

  • Dramatically flatten the nocturnal acid surge, raising gastric pH to 4.0–5.0.

  • Less effective at suppressing postprandial (meal-stimulated) acid secretion because gastrin and vagal acetylcholine signaling pathways remain fully operational.

• Indications and Place in Therapy:

  • Indicated for mild, infrequent heartburn, non-erosive GERD, and episodic dyspepsia (<3 symptomatic episodes per week).

  • Dosed twice daily (morning and evening) to maintain ~50% acid suppression over a 10-hour window.

  • Therapeutic Hierarchy: In severe, erosive esophagitis, active peptic ulcer disease, or ICU stress ulcer prophylaxis, Proton Pump Inhibitors (PPIs) are the gold standard due to superior, complete acid suppression.

• Pharmacokinetics and Renal Elimination:

  • Rapidly absorbed from the gastrointestinal tract with an oral bioavailability of ~50% (for cimetidine and famotidine).

  • Eliminated via a dual mechanism: hepatic metabolism and renal excretion (combined glomerular filtration and active tubular secretion).

  • Elimination half-life ranges from 1 to 4 hours.

  • Dose adjustments are mandatory in patients with renal impairment to prevent drug accumulation and central nervous system toxicity.

Adverse Effects and Drug Interactions of $H_2$ Receptor Antagonists

• Agent-Specific Adverse Effects:

  • Famotidine: Highly selective $H_2$ antagonist with minimal side effects and negligible cytochrome P450 interactions. Top 200 prescribed agent.

  • Cimetidine (Obsolete Agent):

    • Endocrine Dysfunction: Exhibits potent anti-androgenic activity (binds androgen receptors and inhibits dihydrotestosterone) and increases serum prolactin. Causes gynecomastia (breast enlargement) in males and galactorrhea (inappropriate milk secretion) in females.

    • Cytochrome P450 Inhibition: Potent non-selective inhibitor of multiple CYP enzymes (CYP1A2, CYP2C9, CYP2D6, CYP3A4). Dramatically increases the half-life and toxicity risk of co-administered narrow therapeutic index drugs (e.g., warfarin, theophylline, phenytoin).

• Laboratory and Metabolic Interactions:

  • Serum Creatinine Elevation: $H_2$RAs compete directly with endogenous creatinine for active renal tubular secretion transporters. This competition reduces renal creatinine clearance and causes a benign elevation in serum creatinine levels without causing actual renal parenchymal tissue damage.

  • Ethanol Interaction: $H_2$RAs (with the exception of famotidine) inhibit gastric mucosal alcohol dehydrogenase, reducing the first-pass metabolism of ingested ethanol and significantly increasing systemic blood alcohol concentration (particularly in females).

• Inpatient Risk:

  • Intravenous administration of $H_2$RAs in critically ill hospitalized patients increases gastric pH, permitting bacterial colonization of the upper GI tract and increasing the incidence of hospital-acquired pneumonia.

Dialogue & Audience Discussion

• Participant Personal Device & Logistics Discussion:

  • Device Power: A participant noted their computer battery was at 23% and iPad at 32%, expressing surprise since both were fully charged in the morning. Another noted their computer battery regularly drains quickly, but they are content keeping their Lenovo ThinkPad plugged in continuously except when working at a coffee shop without outlets.

  • Lunch Activity: Participant had Chick-Fil-A consisting of a sandwich, chips, and a cookie.

  • Walmart Employee Benefits: Participants expressed amazement regarding Walmart's parental leave policy, noting that female employees receive 5.5 months of fully paid maternity leave, while male employees receive 3 months of fully paid paternity leave.

• Interactive Pharmacotherapy Q&A:

  • Question: Why are second-generation antihistamines like fexofenadine preferred for allergy, while older first-generation drugs like promethazine are prescribed in psychiatric settings?

  • Response: First-generation antihistamines cross the blood-brain barrier easily due to high lipophilicity. Promethazine causes potent central sedation by blocking central receptors. Psychiatrists utilize promethazine synergistically with antipsychotics to sedate agitated patients and control drug-induced extrapyramidal symptoms, rather than for anti-allergic effects.

  • Question: Why do antihistamines sometimes only provide partial relief during severe allergic reactions?

  • Response: Antihistamines selectively block $H_1$ receptors. Severe allergic cascades involve multiple unblocked inflammatory mediators (leukotrienes, prostaglandins, cytokines). Broad anti-inflammatory agents like corticosteroids are required to suppress these additional pathways.

  • Question: Why is an $H_2$ blocker like famotidine sometimes added to an $H_1$ blocker during severe allergic reactions?

  • Response: Massive systemic histamine release during severe hypersensitivity reactions acts on both $H_1$ receptors (causing airway and vascular collapse) and $H_2$ receptors in the stomach (causing hypersecretion of gastric acid and severe stomach pain). Dual blockade treats systemic allergic symptoms while preventing acute acid-induced gastric mucosal injury.

  • Question: Does chronic exposure to $H_2$ antagonists lead to pharmacological tolerance?

  • Response: True pharmacological tolerance to the receptor antagonist does not occur; ongoing or worsening symptoms typically reflect activation of alternative inflammatory/secretory pathways (gastrin or vagal cholinergic stimulation), which require step-up therapy to agents like corticosteroids or proton pump inhibitors.

  • Question: Why are cimetidine prescriptions rarely seen in modern clinical practice?

  • Response: Cimetidine causes significant anti-androgenic side effects (gynecomastia in men, galactorrhea in women) and potently inhibits multiple CYP450 enzymes. Newer $H_2$ antagonists like famotidine provide superior acid suppression without endocrine or metabolic toxicities.